These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 27656025

  • 1. The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
    Lindenbach D, Conti MM, Ostock CY, George JA, Goldenberg AA, Melikhov-Sosin M, Nuss EE, Bishop C.
    J Neurosci; 2016 Sep 21; 36(38):9873-87. PubMed ID: 27656025
    [Abstract] [Full Text] [Related]

  • 2. Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
    Lindenbach D, Conti MM, Ostock CY, Dupre KB, Bishop C.
    Neuroscience; 2015 Dec 03; 310():12-26. PubMed ID: 26363150
    [Abstract] [Full Text] [Related]

  • 3. Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.
    Paolone G, Brugnoli A, Arcuri L, Mercatelli D, Morari M.
    Mov Disord; 2015 Nov 03; 30(13):1728-38. PubMed ID: 26207892
    [Abstract] [Full Text] [Related]

  • 4. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C, Crossman AR, Ravenscroft P.
    Exp Neurol; 2013 Sep 03; 247():476-84. PubMed ID: 23360800
    [Abstract] [Full Text] [Related]

  • 5. GABA storage and release in the medial globus pallidus in L-DOPA-induced dyskinesia priming.
    Nishijima H, Mori F, Arai A, Zhu G, Wakabayashi K, Okada M, Ueno S, Ichinohe N, Suzuki C, Kon T, Tomiyama M.
    Neurobiol Dis; 2020 Sep 03; 143():104979. PubMed ID: 32590036
    [Abstract] [Full Text] [Related]

  • 6. Suppression of presynaptic corticostriatal glutamate activity attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's disease mice.
    Huang YT, Chen YW, Lin TY, Chen JC.
    Neurobiol Dis; 2024 Apr 03; 193():106452. PubMed ID: 38401650
    [Abstract] [Full Text] [Related]

  • 7. Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.
    Perez XA, Zhang D, Bordia T, Quik M.
    Mov Disord; 2017 Apr 03; 32(4):538-548. PubMed ID: 28256010
    [Abstract] [Full Text] [Related]

  • 8. Chronic H3R activation reduces L-Dopa-induced dyskinesia, normalizes cortical GABA and glutamate levels, and increases striatal dopamine D1R mRNA expression in 6-hydroxydopamine-lesioned male rats.
    Avila-Luna A, Gálvez-Rosas A, Aguirre-Pérez A, Hidalgo-Bravo A, Alfaro-Rodriguez A, Ríos C, Arias-Montaño JA, Bueno-Nava A.
    Psychopharmacology (Berl); 2023 Jun 03; 240(6):1221-1234. PubMed ID: 37086286
    [Abstract] [Full Text] [Related]

  • 9. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
    Mela F, Marti M, Dekundy A, Danysz W, Morari M, Cenci MA.
    J Neurochem; 2007 Apr 03; 101(2):483-97. PubMed ID: 17359492
    [Abstract] [Full Text] [Related]

  • 10. Effects of L-dopa priming on cortical high beta and high gamma oscillatory activity in a rodent model of Parkinson's disease.
    Dupre KB, Cruz AV, McCoy AJ, Delaville C, Gerber CM, Eyring KW, Walters JR.
    Neurobiol Dis; 2016 Feb 03; 86():1-15. PubMed ID: 26586558
    [Abstract] [Full Text] [Related]

  • 11. Nociceptin/orphanin FQ receptor agonists attenuate L-DOPA-induced dyskinesias.
    Marti M, Rodi D, Li Q, Guerrini R, Fasano S, Morella I, Tozzi A, Brambilla R, Calabresi P, Simonato M, Bezard E, Morari M.
    J Neurosci; 2012 Nov 14; 32(46):16106-19. PubMed ID: 23152595
    [Abstract] [Full Text] [Related]

  • 12. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F, Millan MJ, Brocco M, Morari M.
    Neuropharmacology; 2010 Feb 14; 58(2):528-36. PubMed ID: 19733554
    [Abstract] [Full Text] [Related]

  • 13. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
    Ravenscroft P, Chalon S, Brotchie JM, Crossman AR.
    Exp Neurol; 2004 Jan 14; 185(1):36-46. PubMed ID: 14697317
    [Abstract] [Full Text] [Related]

  • 14. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1999 Feb 14; 155(2):204-20. PubMed ID: 10072296
    [Abstract] [Full Text] [Related]

  • 15. Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats.
    Kiessling CY, Lanza K, Feinberg E, Bishop C.
    Neuropharmacology; 2020 Sep 01; 174():108138. PubMed ID: 32492451
    [Abstract] [Full Text] [Related]

  • 16. Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
    Lindenbach D, Dupre KB, Eskow Jaunarajs KL, Ostock CY, Goldenberg AA, Bishop C.
    Brain Res; 2013 Nov 06; 1537():327-39. PubMed ID: 24060645
    [Abstract] [Full Text] [Related]

  • 17. Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats.
    Meadows SM, Conti MM, Gross L, Chambers NE, Avnor Y, Ostock CY, Lanza K, Bishop C.
    Mov Disord; 2018 Nov 06; 33(11):1740-1749. PubMed ID: 30485908
    [Abstract] [Full Text] [Related]

  • 18. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
    Marin C, Jiménez A, Tolosa E, Bonastre M, Bové J.
    Synapse; 2004 Feb 06; 51(2):140-50. PubMed ID: 14618681
    [Abstract] [Full Text] [Related]

  • 19. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H, Takahata K, Okano M, Ishikawa T, Satoyoshi H, Nishimura T, Hoshino N, Muraoka S.
    Behav Brain Res; 2018 Jul 16; 347():350-359. PubMed ID: 29526790
    [Abstract] [Full Text] [Related]

  • 20. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
    McCreary AC, Varney MA, Newman-Tancredi A.
    Neuropharmacology; 2016 Jun 16; 105():651-660. PubMed ID: 26777281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.